Fort Washington Investment Advisors 13F: Cuts BMY Stake by $37M

Fort Washington Investment Advisors disclosed a reduced stake in Bristol-Myers Squibb Company (NYSE: BMY) in a filing on October 15, 2026. The firm cut its holdings by 588,083 shares, bringing its total to 1,716,740 shares, valued at about $107.1 million. This represents a decrease of roughly 25.5%.

What Changed in Fort Washington's Bristol-Myers Squibb Position

Fort Washington significantly reduced its position in Bristol-Myers Squibb, going from 2,304,823 shares to 1,716,740 shares. The current value of this position is approximately $107.1 million.

Other Institutional Activity in Bristol-Myers Squibb

Several other institutional investors also adjusted their holdings in Bristol-Myers Squibb. Blackrock Inc. grew its stake by 8,704,215 shares, now holding 180,384,994 shares worth about $10.8 billion. Vanguard Capital Management LLC added 1,018,856 shares, increasing its total to 133,337,856 shares valued at $7.97 billion. Conversely, JPMorgan Chase & Co. decreased its stake significantly by 20,760,371 shares, reducing its holdings to 71,713,442 shares worth around $4.28 billion. Meanwhile, Charles Schwab Investment Management, Inc. raised its position by 6,478,381 shares, totaling 67,595,177 shares valued at approximately $4.04 billion.

Bristol-Myers Squibb Company Stock Up 1.3%

As of October 16, 2026, Bristol-Myers Squibb shares are trading around $60.07, positioned below its 50-day moving average of $63.59 by 5.5%. The stock is also 12.5% lower than its 52-week high of $68.64, but it is 41.3% above its 52-week low of $42.52. The current share price is about 8.5% below the average target price of $65.63 set by analysts.

Recent Earnings

For the trailing twelve months, Bristol-Myers Squibb reported total revenue of approximately $49.19 billion with a net margin of 18.9%. The next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at Bristol-Myers Squibb Company

Recent insider activity includes Chief Financial Officer David Vincent Elkins selling 30,000 shares on April 1, 2026, for a total of about $1.85 million. Officer Phil M. Holzer sold 500 shares on August 25, 2026, at an average price of $67.50, totaling $33,750. Another officer, Cristian Massacesi, sold 6,249 shares on September 9, 2026, for approximately $403,498.

Analysts Set New Price Targets

On October 13, 2026, Wells Fargo maintained its Equal-Weight rating on the stock with a target price of $60.00, down from $65.00. Earlier, on October 5, 2026, Leerink Partners downgraded its rating to Market Perform with a target of $59.00, down from $73.00. Piper Sandler, however, reiterated an Overweight rating with a higher price target of $82.00 on September 16, 2026. The consensus among analysts is a Buy rating with a mean target price of $65.63 based on 24 opinions.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company specializes in developing and selling biopharmaceutical products across various medical fields including oncology and immunology. The recent position changes by Fort Washington and other institutions highlight ongoing shifts in investor sentiment towards the company amidst a competitive healthcare landscape.

Bottom Line

Investors should keep an eye on Bristol-Myers Squibb as it approaches its next earnings report on October 29, 2026. With varying actions taken by institutional investors, the stock's movement in the coming weeks will be worth watching, especially after Fort Washington's recent position cut. This filing may not reflect Fort Washington's current position as the report is backward-looking.